LNA oligonucleotides and the treatment of cancer

a technology of oligonucleotides and cancer, applied in the field of pharmaceutical compositions, can solve the problems of increased cancer recurrence, poor prognosis, resistance to therapy,

Inactive Publication Date: 2006-07-13
ENZON PHARM INC
View PDF8 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Elevated expression of Survivin in tumours is generally associated with poor prognosis, increased cancer recurrence and resistance to therapy, both radiation and chemotherapy.
However, the surprisingly good properties of the LNA oligonucleotides disclosed herein have not yet been described in the prior art.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • LNA oligonucleotides and the treatment of cancer
  • LNA oligonucleotides and the treatment of cancer
  • LNA oligonucleotides and the treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Monomer Synthesis

[0191] The LNA monomer building blocks and derivatives thereof were prepared following published procedures and references cited therein, see:

[0192] WO 03 / 095467 A1

[0193] D. S. Pedersen, C. Rosenbohm, T. Koch (2002) Preparation of LNA Phosphoramidites, Synthesis 6, 802-808.

[0194] M. D. Sørensen, L. Kværnø, T. Bryld, A. E. Håkansson, B. Verbeure, G. Gaubert, P. Herdewijn, 3. Wengel (2002) α-L-ribo-configured Locked Nucleic Acid (α-l-LNA): Synthesis and Properties, J. Am. Chem. Soc., 124, 2164-2176.

[0195] S. K. Singh, R. Kumar, J. Wengel (1998) Synthesis of Novel Bicyclo[2.2.1] Ribonucleosides: 2′-Amino- and 2′-Thio-LNA Monomeric Nucleosides, J. Org. Chem. 1998, 63, 6078-6079.

[0196] C. Rosenbohm, S. M. Christensen, M. D. Sørensen, D. S. Pedersen, L. E. Larsen, J. Wengel, T. Koch (2003) Synthesis of 2′-amino-LNA: a new strategy, Org. Biomol. Chem. 1, 655-663. D. S. Pedersen, T. Koch (2003) Analogues of LNA (Locked Nucleic Acid). Synthesis of the 2′-Thio-LNA Thymi...

example 2

Oligonucleotide Synthesis

[0197] Oligonucleotides were synthesized using the phosphoramidite approach on an Expedite 8900 / MOSS synthesizer (Multiple Oligonucleotide Synthesis System) at 1 μmol or 15 μmol scale. For larger scale synthesis an Äkta Oligo Pilot was used. At the end of the synthesis (DMT-on), the oligonucleotides were cleaved from the solid support using aqueous ammonia for 1-2 hours at room temperature, and further deprotected for 4 hours at 65° C. The oligonucleotides were purified by reverse phase HPLC (RP-HPLC). After the removal of the DMT-group, the oligonucleotides were characterized by AE-HPLC, RP-HPLC, and CGE and the molecular mass was further confirmed by ESI-MS. See below for more details.

[0198] Preparation of the LNA-Solid Support:

[0199] Preparation of the LNA Succinyl Hemiester

[0200] 5′-O-DMT-3′-hydroxy-LNA monomer (500 mg), succinic anhydride (1.2 eq.) and DMAP (1.2 eq.) were dissolved in DCM (35 mL). The reaction was stirred at room temperature overnig...

example 3

Design of the LNA Oligonucleotide

[0220]

TABLE 2LNA OligonucleotidesSEQIDNO.Sequence and designdesigns15′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′25′-MeCsTsMeCsAsastscscsastsgsgsMeCsAsGsc-3′4-8-3-1Reducing the amount of phosphorothioate links35′-MeCTMeCAsastscscsastsgsgsMeCAGsc-3′4-8-3-145′-MeCTMeCAsastscscsastsgsgsMeCAGc-3′4-8-3-1Reducing the amount of LNA monomers units55′-MeCsTsMeCsAsastscscsastsgsgsMeCsAsgsc-3′4-8-2-265′-csTsMeCsAsastscscsastsgsgsMeCsAsGsc-3′1-3-8-3-1Reducing the amount of phosphorothioatelinks and LNA monomers units75′-MeCTMeCAsastscscsastsgsgsMeCAgsc-3′4-8-2-285′-csTMeCAsastscscsastsgsgsMeCAGsc-3′1-3-8-3-195′-MeCTMeCAsastscscsastsgsgsMeCAgc-3′4-8-2-2105′-cTMeCAsastscscsastsgsgsMeCAGc-3′1-3-8-3-1LNA oligonucleotides containing a-L-LNA monomer units115′-MeCasTasMeCasAasastscscsastsgsgsMeCasAasGasc-3′4-8-3-1125′-MeCsTsMeCsAasastscscsastsgsgsMeCasAsGsc-3′4-8-3-1135′-MeCaTaMeCaAasastscscsastsgsgsMeCaAaGasc-3′4-8-3-1145′-MeCaTaMeCaAasastscscsastsgsgsMeCaAaGac-3′4-8-3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
ionic strengthaaaaaaaaaa
volumeaaaaaaaaaa
ionic strengthaaaaaaaaaa
Login to view more

Abstract

The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo. The LNA oligonucleotides are superior to other LNA oligonucletides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down-regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.

Description

FIELD OF THE INVENTION [0001] The present invention provides pharmaceutical compositions useful for the treatment of cancer. The compositions comprise a particular LNA oligonucleotide having excellent properties with respect to the inhibition of the expression of Survivin. The present invention also provides a method for treating cancer, and various kits. BACKGROUND OF THE INVENTION [0002] Survivin is one of the most attractive novel cancer targets. The clinical role of Survivin in cancer has been emphasised by detection of high levels of this protein in almost all tumour types. Elevated expression of Survivin in tumours is generally associated with poor prognosis, increased cancer recurrence and resistance to therapy, both radiation and chemotherapy. The fact that expression of Survivin is, with a few exceptions, not found in normal adult tissues makes Survivin a pivotal cancer gene. [0003] The inhibitor of apoptosis protein (IAP) Survivin is implicated in two key biological events...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C12N15/113
CPCA61K38/00C12N15/1135C12N2310/11C12N2310/315C12N2310/319C12N2310/3341A61P35/00A61P35/02A61P43/00C12N15/113A61K31/7088
Inventor ROSENBOHM, CHRISTOPHKJAERULFF, LENEWESTERGAARD, MAJKENWISSENBACH, MARGITHANSEN, JENSASKLUND, MARLENE
Owner ENZON PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap